The Alzheimer’s field was dealt another body blow yesterday with the announcement of a premature end to testing of Novartis/Amgen’s BACE inhibitor CNP520, aka umibecestat, in two Phase 2/3 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback